Status:
COMPLETED
Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors
Lead Sponsor:
Jose Seijas Amigo
Conditions:
Cognitive Function
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Brief Summary
The main objective will be to evaluate the changes in the cognitive function in naive patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal Cognitive Assesment quest...
Eligibility Criteria
Inclusion
- Patients 18 years old or over
- To start with the first funded dose of PCSK9 inhibitors ( LDL \> 100 mg/dL)
- Maximum dose or statin intolerance
Exclusion
- Diagnosis of any disease related with cognitive deterioration
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04319081
Start Date
March 1 2020
End Date
January 13 2023
Last Update
January 17 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Virxen da Xunqueira de Cee
Cee, A Coruña, Spain
2
Hospital Arquiteto Marcide de Ferrol
Ferrol, A Coruña, Spain
3
Hospital del Barbanza
Ribeira, A Coruña, Spain
4
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain